1. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP.
- Author
-
Brannagan TH 3rd, Pradhan A, Heiman-Patterson T, Winkelman AC, Styler MJ, Topolsky DL, Crilley PA, Schwartzman RJ, Brodsky I, and Gladstone DE
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating immunology, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating physiopathology, Stem Cells immunology, Treatment Outcome, Cyclophosphamide administration & dosage, Immunosuppressive Agents administration & dosage, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating drug therapy, Stem Cell Transplantation
- Abstract
Four patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who were refractory to conventional treatment were treated with high-dose cyclophosphamide (200 mg/kg over 4 days). All improved in functional status and muscle strength. Nerve conduction studies improved in three of four. Other immunomodulatory medications have been discontinued. High-dose cyclophosphamide can be given safely to patients with CIDP and patients with disease persistence after standard therapy may have a response that lasts for over 3 years and results in long-term disease remission.
- Published
- 2002
- Full Text
- View/download PDF